DGAP-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Dividend 
Drägerwerk AG & Co. KGaA: preliminary results for 2020, dividend and guidance for 2021 
13-Jan-2021 / 19:22 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ad-hoc notification in accordance with Sec. 17 of the MAR 
Drägerwerk AG & Co. KGaA: preliminary results for 2020, dividend and guidance for 2021 
Lübeck, 13 January 2021 - Dräger hereby announces preliminary, unaudited business figures for the 2020 financial year. 
Due to the strong demand in the course of the corona pandemic, business development in 2020 in terms of net sales and 
earnings was significantly above the previous year's level. Over the year, incoming orders increased by around 35.7 
percent (around 39.2 percent net of currency effects). As a result, net sales rose significantly by around 22.6 percent 
(around 25.8 percent net of currency effects) to around 3.41 billion euros (2019: 2.78 billion euros). Due to the high 
net sales volume and a higher gross profit margin, earnings before interest and taxes (EBIT) also increased 
significantly. EBIT is expected to be between 385 and 395 million euros (2019: 66.6 million euros), which would 
correspond to an EBIT margin of between 11.3 and 11.6 percent (2019: 2.4 percent). 
Net sales growth and the EBIT margin therefore exceeded the range most recently forecast by Dräger (currency-adjusted 
net sales growth between 14.0 and 22.0 percent and an EBIT margin between 7.0 and 11.0 percent). 
Due to the corona pandemic, the demand in medical was particularly high. Net sales in the medical division rose by 
around 32.3 percent (around 36.1 percent net of currency effects). Net sales in the safety division were also above the 
previous year's level, with growth of around 6.2 percent (around 8.5 percent net of currency effects). The demand for 
light breathing protection (FFP masks / N95 masks) was very strong due to the pandemic. 
Guidance 2021: 
Against the background of decreasing influences from the corona pandemic, the strong business development in 2020 will 
not repeat itself in 2021. Dräger expects currency-adjusted net sales to shrink between -7.0 and -11.0 percent in the 
fiscal year 2021. Dräger forecasts an EBIT margin between 5.0 and 8.0 percent. The assessment regarding the margin 
development provided assumes unchanged exchange rates. 
Dividend: 
The cancellation of the participation certificates in 2020 resulted in a sharp increase in net debt. The equity ratio 
fell from 41.9 percent at the end of 2019 to 31.0 percent at the end of the third quarter of 2020. Against this 
background, the Management Board decided today, after the preliminary 2020 business figures were available, to propose 
a higher retention of profits to the Annual General Meeting. Until the equity ratio reaches a level of over 40 percent 
again, Dräger will keep the dividend at the previous year's level. Accordingly, the Management Board will propose a 
dividend of EUR 0.13 per common share and EUR 0.19 per preferred share to the General Meeting. The dividend proposal is 
still subject to the approval of the supervisory board. 
Dräger will publish its full, audited results for fiscal year 2020 on March 4, 2021. 
Drägerwerk AG & Co. KGaA 
Moislinger Allee 53-55 
23558 Lübeck, Deutschland 
www.draeger.com 
Investor Relations: 
Thomas Fischler 
Tel. +49 451 882-2685 
thomas.fischler@draeger.com 
Corporate Communications: 
Melanie Kamann 
Tel. +49 451 882-3998 
melanie.kamann@draeger.com 
Disclaimer 
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are 
based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information 
available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor 
assume any responsibility for the future developments and results described above. These are dependent on a number of 
factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions 
which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking 
statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. 
Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative 
performance measures used. 
=---------------------------------------------------------------------------------------------------------------------- 
13-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Drägerwerk AG & Co. KGaA 
              Moislinger Allee 53-55 
              23542 Lübeck 
              Germany 
Phone:        +49 (0)451 882-0 
Fax:          +49 (0)451 882-2080 
E-mail:       info@draeger.com 
Internet:     www.draeger.com 
ISIN:         DE0005550602, DE 000 555 063 6, DE 000 555 065 1, DE 000 555 067 7, DE 000 555 071 9 
WKN:          555060, 555063 Vorzüge, 555065 Genussschein A, 555067 Genussschein K, 555071 Genussschein D 
Indices:      TecDAX 
Listed:       Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich; Regulated 
              Unofficial Market in Stuttgart, Tradegate Exchange 
EQS News ID:  1160496 
 
End of Announcement  DGAP News Service 
=------------ 

1160496 13-Jan-2021 CET/CEST

(END) Dow Jones Newswires

January 13, 2021 13:23 ET (18:23 GMT)